HYDROCHLOROTHIAZIDE TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
24-05-2022
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
HYDROCHLOROTHIAZIDE
Tilgjengelig fra:
PRO DOC LIMITEE
ATC-kode:
C03AA03
INN (International Name):
HYDROCHLOROTHIAZIDE
Dosering :
50MG
Legemiddelform:
TABLET
Sammensetning:
HYDROCHLOROTHIAZIDE 50MG
Administreringsrute:
ORAL
Enheter i pakken:
100
Resept typen:
Prescription
Terapeutisk område:
THIAZIDE DIURETICS
Produkt oppsummering:
Active ingredient group (AIG) number: 0101048001; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2019-04-01
Preparatomtale
HYDROCHLOROTHIAZIDE Product Monograph Page 1 of 23
PRODUCT MONOGRAPH
PR
HYDROCHLOROTHIAZIDE
Hydrochlorothiazide Tablets USP
25 mg and 50 mg
DIURETIC - ANTIHYPERTENSIVE
Pro Doc Ltée
2925 Boul Industriel
Laval, Quebec
H7L 3W9
www.prodoc.qc.ca
Submission Control No: 263745
Date of Revision:
May 24, 2022
HYDROCHLOROTHIAZIDE Product Monograph Page 1 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
2
SUMMARY
PRODUCT
INFORMATION
..............................................................................................
2
INDICATIONS
AND
CLINICAL
USE
....................................................................................................
2
CONTRAINDICATIONS
.........................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................
3
ADVERSE
REACTIONS
.........................................................................................................................
7
DRUG
INTERACTIONS
..........................................................................................................................
7
DOSAGE
AND
ADMINISTRATION
....................................................................................................
11
OVERDOSAGE
......................................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
..................................................................................
12
STORAGE
AND
STABILITY
................................................................................................................
13
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
....................................................................
13
PART II: SCIENTIFIC INFORMATION
..................................................................
Les hele dokumentet
